[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beone Medicines Ltd (ONC)

Beone Medicines Ltd (ONC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,757,748
  • Shares Outstanding, K 109,720
  • Annual Sales, $ 5,343 M
  • Annual Income, $ 286,930 K
  • EBIT $ 686 M
  • EBITDA $ 828 M
  • 60-Month Beta 0.49
  • Price/Sales 6.71
  • Price/Cash Flow 83.61
  • Price/Book 7.53

Options Overview Details

View History
  • Implied Volatility 43.71% (-1.19%)
  • Historical Volatility 25.76%
  • IV Percentile 36%
  • IV Rank 30.43%
  • IV High 56.45% on 11/05/25
  • IV Low 38.14% on 01/16/26
  • Expected Move (DTE 26) 14.45 (4.43%)
  • Put/Call Vol Ratio 0.83
  • Today's Volume 11
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 2,257
  • Open Int (30-Day) 2,233
  • Expected Range 311.45 to 340.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.40
  • Number of Estimates 1
  • High Estimate $1.40
  • Low Estimate $1.40
  • Prior Year $0.84
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
272.75 +19.49%
on 06/26/26
331.52 -1.70%
on 07/24/26
+48.78 (+17.60%)
since 06/24/26
3-Month
253.95 +28.33%
on 06/11/26
331.52 -1.70%
on 07/24/26
+25.10 (+8.34%)
since 04/24/26
52-Week
253.95 +28.33%
on 06/11/26
385.22 -15.40%
on 11/17/25
+29.44 (+9.93%)
since 07/24/25

Most Recent Stories

More News
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities ...

ONC : 325.90 (-0.27%)
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets...

ONC : 325.90 (-0.27%)
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p

ONC : 325.90 (-0.27%)
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment ...

ONC : 325.90 (-0.27%)
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk features New European patient research...

ONC : 325.90 (-0.27%)
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said...

ONC : 325.90 (-0.27%)
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to...

ONC : 325.90 (-0.27%)
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy ...

ONC : 325.90 (-0.27%)
3 Gold-Medal Mutual Funds to Buy Now

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 206.84 (-0.92%)
GOOGL : 319.74 (+0.65%)
ONC : 325.90 (-0.27%)
TDVG : 49.59 (+0.49%)
RYTM : 102.10 (-0.55%)
MU : 920.95 (-6.99%)
DODIX : 12.51 (+0.16%)
V : 355.74 (+1.18%)
ROST : 238.89 (+2.80%)
PRDGX : 89.98 (+0.63%)
CB : 359.75 (+1.84%)
WMT : 109.47 (+0.99%)
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA ...

ONC : 325.90 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.

See More

Key Turning Points

3rd Resistance Point 336.57
2nd Resistance Point 334.05
1st Resistance Point 329.97
Last Price 325.90
1st Support Level 323.37
2nd Support Level 320.85
3rd Support Level 316.77

See More

52-Week High 385.22
Fibonacci 61.8% 335.07
Last Price 325.90
Fibonacci 50% 319.58
Fibonacci 38.2% 304.09
52-Week Low 253.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.